Navigation Links
Melatonin shows potential to slow tumor growth in certain breast cancers

DETROIT An early stage study shows melatonin a hormone that regulates the body's sleep and awake cycles may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of So Paulo.

The study, published online in the journal PLoS One, finds that melatonin may inhibit tumor growth and cell production, as well as block the formation of new blood vessels in ER-negative breast cancer models.

"These early stage research results with the melatonin drug in a triple-negative breast cancer animal models achieved in our lab has not been seen anywhere else," says study co-author Adarsh Shankar, a research assistant in the Department of Radiology at Henry Ford Hospital.

"The key finding of the study is that we now know that we can trace this drug and its effect on tumor growth, which opens the door for more research on this topic."

Melatonin is a hormone naturally produced by the brain's pineal gland in response to darkness, and it is also available as a man-made supplement.

Because of melatonin's suspected antioxidant properties, some believe it may suppress the growth of some types of cancer cells, especially when combined with certain anti-cancer drugs, according to the American Cancer Society.

A promising tactic in limiting cancer progression is controlling angiogenesis, the formation of new blood vessels. Once a tumor exceeds a few millimeters in diameter, hypoxia (lack of oxygen) triggers a cascade of events to allow angiogenesis and tumor progression.

To determine the therapeutic effectiveness of melatonin on tumor growth, the Henry Ford Hospital and Foundation for Research Support of the State of So Paulo researchers evaluated the action of melatonin on angiogenesis in ER-negative breast cancer in vitro and in vivo using cell and mouse models respectively.

The mice were randomly assigned to either the melatonin or control groups. The melatonin group received treatment each night for 21 days; melatonin was administered at pharmacologic concentration one hour before room lighting was switched off. Melatonin administered prior to the nocturnal is believed to be more effective because tissues are most sensitive to the hormone at this time.

At the end of the 21-day treatment, researchers used single photon emission computed tomography (SPECT) to determine whether melatonin therapy effectively decreased the size of implanted human triple negative breast cancer in the mouse models and if there was be any changes in the formation of new blood vessels.

Additionally, tumor volume was measured each week and tumor tissue was analyzed at the end of treatment.

The study found that none of the treated mice showed any loss of weight and lethargy during the 21-day treatment; instead, most showed excessive movement but no irritability or aggressive behavior.

Those treated showed significantly smaller tumors after 21 days while the mean tumor volume increased significantly in the control group. And, there was less vascular growth in the tumors of the treated group.

Results were also replicated in cell models.

The study showed that melatonin administered at pharmacologic concentration was able to reduce ER-negative breast cancer cell viability in vitro.

These results suggest that melatonin has the potential as a therapeutic agent for breast cancer.

The study's authors caution, however, that this research is still in its very early stages and results are not yet ready to be translated for patient use.

More basic research is needed on this topic particularly on how melatonin acts on angiogenesis in various cancers before clinical trials with humans can be planned.


Contact: Krista Hopson
Henry Ford Health System

Related medicine news :

1. Spread of Cancer May be Reduced by Maximizing Melatonin by Blocking Blue Light Says Photonic Developments LLC
2. Study Suggests Link Between Hormone Melatonin and Type 2 Diabetes
3. Melatonin may lower prostate cancer risk
4. Wellesley study shows income inequality a key factor in high US teen births
5. Invasive heart test being dramatically overused, Stanford study shows
6. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
7. Lung Cancer Screening Might Pay Off, Analysis Shows
8. Nonsurgical Method to Measure Brain Pressure Shows Promise
9. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
10. Study Shows New Option for Kids With Tough-to-Treat Leukemia
11. Politics May Get in the Way of Empathy, Research Shows
Post Your Comments:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor ... Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension (PH) ... nominated by the public, will receive special recognition throughout 2016 as part of ...
(Date:11/25/2015)... ... 25, 2015 , ... Privately owned Contract Development and Manufacturing ... its current state of the art research, development and manufacturing facility outside of ... manufacturing capacity as well as to support its clients’ growing research and development ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of ... weight gain, cold hands, and dry skin. But many people who find their cholesterol ... exercise regimen instead of their thyroid, especially if they don’t have any of the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Today AVACEN Medical announced the issue of United States patent ... Adjustment ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific ... Photo - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
Breaking Medicine Technology: